Reproducibility of PD-L1 assessment in non-small cell lung cancer—know your limits but never stop trying to exceed them

Por Ilie, Marius, Hofman, Paul
Publicado no Transl Lung Cancer Res (2017)

Editorial for “Longitudinal cell-free DNA analysis in patients with small cell lung cancer reveals...

Por Fleischhacker, Michael, Schmidt, Bernd
Publicado no Transl Lung Cancer Res (2018)

ASCEND-2: a canary in a coal mine for descending to second-line treatment for ALK-rearranged non-small cell lung cancer

Por Zhu, Viola W., Ou, Sai-Hong Ignatius
Publicado no Transl Lung Cancer Res (2016)

Cytology versus histology for programmed death-ligand 1 expression evaluation in the landscape of non-small cell lung cancer patients selection for immunotherapy

Por Malapelle, Umberto, Iaccarino, Antonino, Rossi, Antonio
Publicado no Transl Lung Cancer Res (2018)

DARPP-32 and t-DARPP isoform in non-small cell lung cancer (NSCLC): could they drive patients’ clinical management and be a therapeutic target?

Por Lamberti, Giuseppe, Peterle, Chiara, Gelsomino, Francesco
Publicado no Transl Lung Cancer Res (2018)

A new addition to the PD-1 checkpoint inhibitors for non-small cell lung cancer—the anti-PDL1 antibody—MEDI4736

Por Lee, Sylvia M., Chow, Laura Q.
Publicado no Transl Lung Cancer Res (2014)

Erratum: The association between human papillomavirus presence and epidermal growth factor receptor mutations in Asian patients with non-small cell lung cancer

Por Liang, Hengrui, Pan, Zhenkui, Cai, Xiuyu, Wang, Wei, Guo, Chengye, He, Jiaxi, Chen, Yuehan, Liu, Zhichao, Wang, Bo, He, Jianxing, Liang, Wenhua
Publicado no Transl Lung Cancer Res (2018)

Grb2-associated binder-2 gene promotes migration of non-small cell lung cancer cells via Akt signaling pathway

Por Xu, Li Jun, Wang, Yu Chang, Lan, Hong Wen, Li, Jun, Xia, Tian
Publicado no Am J Transl Res (2016)

miR-223/FBW7 axis regulates doxorubicin sensitivity through epithelial mesenchymal transition in non-small cell lung cancer

Por Li, Renyuan, Wu, Shengjun, Chen, Xin, Xu, Hongfei, Teng, Peng, Li, Weidong
Publicado no Am J Transl Res (2016)

Routine clinical use of circulating tumor cells for diagnosis of mutations and chromosomal rearrangements in non-small cell lung cancer—ready for prime-time?

Por Pailler, Emma, Faugeroux, Vincent, Oulhen, Marianne, Catelain, Cyril, Farace, Françoise
Publicado no Transl Lung Cancer Res (2017)

LncRNA PICART1 suppressed non-small cell lung cancer cells proliferation and invasion by targeting AKT1 signaling pathway

Por Zhang, Chunling, Su, Chuanzhi, Song, Qi, Dong, Fushi, Yu, Shihuan, Huo, Jianmin
Publicado no Am J Transl Res (2018)

Long noncoding RNA LINC01296 induces non-small cell lung cancer growth and progression through sponging miR-5095

Por Hu, Xuefei, Duan, Liang, Liu, Hongcheng, Zhang, Lei
Publicado no Am J Transl Res (2019)

Therapy of (125)I particles implantation inhibited the local growth of advanced non-small cell lung cancer: a retrospective clinical study

Por Dai, Fuhong, Wang, Jiangye, An, Hongshan, Lei, Ting, Tang, Ke, Ma, Xiaochun, Duo, Peng, Ren, Pengyun, Chai, Wenxiao
Publicado no Am J Transl Res (2019)

Copper-transporting P-type adenosine triphosphatase (ATP7A) is associated with platinum-resistance in non-small cell lung cancer (NSCLC)

Por Li, Zhuang-hua, Qiu, Miao-zhen, Zeng, Zhao-lei, Luo, Hui-yan, Wu, Wen-jing, Wang, Feng, Wang, Zhi-qiang, Zhang, Dong-sheng, Li, Yu-hong, Xu, Rui-hua
Publicado em 2012

Prognostic role of pretreatment neutrophil-to-lymphocyte ratio in non-small cell lung cancer patients treated with systemic therapy: a meta-analysis

Por Wang, Zimu, Zhan, Ping, Lv, Yanling, Shen, Kaikai, Wei, Yuqing, Liu, Hongbing, Song, Yong
Publicado no Transl Lung Cancer Res (2019)

Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer

Por Chen, Fangfang, Yao, Yanwen, Ma, Chunyan, Ma, Xingqun, Wang, Zhaofeng, Lv, Tangfeng, Xiao, Xinwu, Yin, Jie, Song, Yong
Publicado no Transl Lung Cancer Res (2015)

ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation

Por Karachaliou, Niki, Gimenez-Capitan, Ana, Drozdowskyj, Ana, Viteri, Santiago, Moran, Teresa, Carcereny, Enric, Massuti, Bartomeu, Vergnenegre, Alain, de Marinis, Filippo, Molina, Miguel Angel, Teixido, Cristina, Rosell, Rafael
Publicado no Transl Lung Cancer Res (2014)

LncRNA Sox2ot overexpression serves as a poor prognostic biomarker in gastric cancer

Por Zhang, Yuanyuan, Yang, Rui, Lian, Jianchun, Xu, Haiyan
Publicado no Am J Transl Res (2016)

Answer/comment to Prof. Tammemagi’s article “Selecting lung cancer screenees using risk prediction models—where do we go from here”

Por Røe, Oluf Dimitri
Publicado no Transl Lung Cancer Res (2019)

Nivolumab as first-line treatment in non-small cell lung cancer patients—key factors: tumor mutation burden and PD-L1 ≥50%

Por Zarogoulidis, Paul, Papadopoulos, Vasilis, Maragouli, Elena, Papatsibas, George, Sardeli, Chrysanthi, Man, Yan-Gao, Bai, Chong, Huang, Haidong
Publicado no Transl Lung Cancer Res (2018)